Dove Medical Press podcasts

Dr Uwe Wollina, the former head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Merola and Amin to discuss the potential triggers of an acute GPP flare. GPP can be debilitating for patients, and they will discuss the different aspects of the burden of disease for patients with GPP.
Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus, its diagnosis is challenging. The onset of symptoms is rapid, with the appearance of painful skin erythema, followed by the widespread eruption of sterile pustules. Acute GPP (called a flare) is often accompanied by systemic symptoms, including high fever, pain in skin lesions, malaise, and fatigue. Approximately half of GPP flares require hospitalization, with an average inpatient duration of 10–14 days. GPP prevalence estimates range from approximately 2–124 cases per million persons, with a female predominance. The most common age of onset of GPP is 40–60 years, although cases have been described in younger adults and children. GPP affects every aspect of patients’ lives and has a high physical and psycho-social impact. Recent research on the interleukin-36 pathway associated with GPP led to the development of a GPP-specific treatment, spesolimab, which was approved by the US FDA in September 2022. This podcast explores the clinical presentation, disease course, and burden of disease in GPP, including differential diagnosis and common triggers of an acute flare.

Dr Jason Hawkes, a board-certified medical dermatologist in the Greater Sacramento area welcomes Drs. Bhutani and Reisner, to discuss the clinical presentation of GPP, the patient journey, diagnostic challenges, and novel management strategies from the perspective of the patient and provider.
Generalized pustular psoriasis (GPP) is a rare, chronic, and debilitating disease characterized by flares of widespread erythema, desquamation, and pustule formation. GPP flares can be accompanied by systemic symptoms including fever, fatigue, malaise, and skin pain; severe cases may be fatal if untreated. Although GPP may occur concurrently with plaque psoriasis, they represent two distinct inflammatory conditions. Patients with GPP experience a substantial burden of disease, and the impact of GPP on an individual’s mental health and quality-of-life (QoL) goes far beyond skin pain and discomfort. The rarity of GPP may result in a misdiagnosis, as the sudden onset of skin pustules may be mistaken for a primary infection. Misdiagnosis with a subsequent delay in treatment has tremendous negative consequences for the affected patient. In September 2022, spesolimab became the first FDA-approved medication in the US for the treatment of GPP flares in adults. Spesolimab has since been approved by regulatory agencies in numerous countries, including Japan, Mainland China, and the EU. Prior to spesolimab, the clinical management of GPP relied on the off-label use of systemic or biologic therapies approved for plaque psoriasis or other inflammatory conditions. There is a need for increased education among healthcare providers regarding the clinical diagnosis, risk stratification, and therapeutic management of this rare disease, including the other novel GPP-specific therapies in development. In this podcast, two dermatologists and a patient who has plaque psoriasis and GPP discuss the clinical presentation, symptoms, disease burden, QoL impacts, diagnostic challenges, and therapeutic strategies for the management of GPP.

Dr Stanley Cohen, the Department of Internal Medicine, University of Texas Southwestern Medical Center, and Mariah Z. Leach, Mamas Facing Forward, Colorado, discuss some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The podcast also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.
This podcast is intended for health care professionals and patients with the aim of discussing some of the concerns that patients may have about initiating treatment with a biosimilar, or switching from their current medication to a biosimilar, for Rheumatoid Arthritis. The podcast also covers the definitions of a biosimilar, interchangeable biosimilar, and switching, before discussing the available data supporting the efficacy and safety of biosimilars in Rheumatoid Arthritis.
The authors of this podcast include Stanley Cohen, MD, Professor at University of Texas Southwestern Dallas, TX, and Mariah Z. Leach, who is a patient advocate and the founder of Mamas Facing Forward in Louisville, Colorado. This podcast has not been peer-reviewed but has been vetted by the journal’s Editor-in-Chief.  Content and technical support were provided by Envision Pharma Group, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). for these services. BIPI was given the opportunity to review earlier talking points and the final transcript for medical and scientific accuracy, as well as intellectual property considerations. Copyright © 2023, Boehringer Ingelheim Pharmaceuticals, Inc.. All rights reserved.

Dr Uwe Wollina, the head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Clive Liu and Eingun James Song, who are both dermatologists in Washington State to discuss their experiences in treating generalized pustular psoriasis, also referred to as GPP.
Acute episodes of generalized pustular psoriasis (GPP), known as “flares,” are characterized by the widespread appearance of pustules with surrounding skin erythema, and are often accompanied by systemic symptoms. The clinical course of GPP is unpredictable, and symptoms vary in extent and severity; the disease may be relapsing-remitting with recurrent episodes of pustulosis, or be more persistent. The triggers that may lead to flares include withdrawal of corticosteroids, stress, pregnancy, and infections. GPP-specific assessment tools, such as the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) and the General Pustular Psoriasis Area and Severity Index (GPPASI), were developed to evaluate the severity of disease, and to monitor the patient’s response to therapy during clinical trials. Spesolimab is the first GPP-specific treatment available in the United States for the treatment of GPP flares in adults, and was approved by the US FDA in September 2022. To date, spesolimab has been approved by regulatory agencies in almost 40 countries, including Japan, Mainland China, and the European Union. Spesolimab is a first-in-class humanized monoclonal antibody that targets the interleukin-36 receptor, and blocks the downstream effects of the interleukin-36 pathway, which is associated with GPP pathogenesis. Data from clinical trials demonstrate the safety and efficacy of spesolimab in providing rapid clinical improvement for patients with GPP flares. Standardized international guidelines for the diagnosis and management of GPP are needed, and no recent GPP guidelines are available in the US. This podcast discusses clinical assessment tools for GPP (GPPGA and GPPASI), the evolution of GPP management guidelines, the therapeutic landscape of GPP, efficacy and safety data for spesolimab, and examines important considerations for patients living with this condition.

Dr Uwe Wollina, the head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Bhutani and Hawkes, both board-certified dermatologists in California to discuss their experiences in treating generalized pustular psoriasis, also referred to as GPP.
Generalized pustular psoriasis is a rare presentation of psoriatic disease and is characterized by the acute onset of diffuse superficial pustules on the skin. These pustules can often coalesce, forming what’s known as ‘lakes of pus’ that are most often seen on the trunk and on skin folds. GPP flares are often accompanied by systemic symptoms, including fever, malaise, and edema. The interleukin (IL)-36 pathway plays a central role in the development of GPP, although several other genes may be associated with GPP. The rarity of GPP makes its diagnosis challenging and it could be mistaken for an infectious condition or other types of pustular psoriasis, including unstable forms of psoriasis that may present with pustules. Performing a thorough skin examination and obtaining a detailed history are vital to exclude these differential diagnoses. Incorrect or late diagnosis, inadequate or delayed treatment, and lack of specialist referrals may contribute to increased disease severity and can have a debilitating impact on patients’ quality of life. In this podcast, two US-based dermatologists discuss the clinical characteristics of GPP, highlight the central role of IL-36 in immunopathogenesis, and share practical approaches to recognizing and diagnosing the disease.

Dr John Kane, discusses negative symptoms in schizophrenia alongside fellow expert, Dr William Carpenter, and Mr Matthew Racher, a Certified Recovery Peer Specialist and dedicated advocate for people living with schizophrenia, who is currently studying for his Master of Social Work (MSW) in Miami, Florida. In this podcast, the authors discuss challenges and opportunities faced by patients and clinicians in the assessment and treatment of negative symptoms. They also touch upon emerging therapeutic strategies, with the aim of raising awareness of the unmet therapeutic needs of those living with negative symptoms. Mr Racher provides a unique patient perspective to this discussion, drawing on his own daily experiences of living with negative symptoms, as well as offering positive insights from his recovery from schizophrenia.
Author Biographies
Dr John Kane is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, a recipient of the Arthur P. Noyes Award in Schizophrenia, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.
Dr William Carpenter, MD, is a professor of psychiatry at the University of Maryland School of Medicine, is Editor-in-Chief for Schizophrenia Bulletin. Dr Carpenter’s main research focus is in the area of schizophrenia, and was awarded The Rhoda and Bernard Sarnat International Prize in Mental Health (Institute of Medicine of the National Academy of Sciences, 2013), the Schizophrenia International Research Society (SIRS) Lifetime Achievement Award (SIRS, 2019) and the Pardes Humanitarian Prize in Mental Health (Brain and Behaviour Research Foundation, 2019). 
Mr Matthew Racher is a Certified Recovery Peer Specialist and dedicated advocate for people living with schizophrenia, who is currently studying for his Master of Social Work (MSW) in Miami, Florida. Mr Racher’s aim is to draw upon his own lived experience in recovery from schizophrenia to help others manage and overcome their own mental health challenges. Alongside his involvement in Miami-Dade’s local National Alliance on Mental Illness (NAMI) affiliate, he is also a keen and talented musician, who performs in the band FogDog alongside Mr Carlos Larrauri and whose music can be heard in this podcast.

Dr John Kane, a clinical expert in schizophrenia, discusses cognitive impairments in schizophrenia with fellow expert Dr Philip D. Harvey and patient advocate and mental health clinician, Mr Carlos Larrauri, who was diagnosed with schizophrenia. The podcast aims to raise awareness of the unmet need to address cognitive impairments associated with schizophrenia (CIAS) as well as the challenges/opportunities faced by patients and clinicians regarding assessments and treatments. The authors emphasize the importance of a treatment focus on daily functioning, in parallel with cognitive symptoms, to mitigate impairments and improve overall outcomes. Mr Larrauri presents the patient perspective and shares his experiences of how psychosocial support and cognitive training can benefit recovery and help patients achieve their goals.
Author Biographies
Dr John Kane is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, a recipient of the Arthur P. Noyes Award in Schizophrenia, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.
Dr Philip D. Harvey is Leonard M. Miller Professor of Psychiatry, vice chair for research, and director of the Division of Psychology at the University of Miami Miller School of Medicine, and has also received a number of awards for research and has authored over 1,000 scientific papers and abstracts and written over 60 book chapters. 
Mr Carlos A. Larrauri, MSN, is a mental health clinician, and member of the National Alliance on Mental Illness (NAMI) Board of Directors who was diagnosed with schizophrenia at 23 years of age. He has previously published on cognition and functioning in schizophrenia with Dr. Harvey, and is currently pursuing a law degree at the University of Michigan Law School, and a concurrent master’s in public administration at the Harvard Kennedy School, where he is a Zuckerman Fellow at Harvard’s Center for Public Leadership. He also writes original music and performs in the band FogDog alongside Mr Matthew Racher, whose music can be heard in this podcast.

In the final episode of Season 4, Dr Surya Bhatt is here to discuss the influence of continued smoking on COPD with Dr Richard Russell. They will discuss how smoking can impact treatment decisions, how we can get our patients to stop smoking and the effects smoking can have on COPD outcomes.1–3 Dr Russell will then dive into a new publication on the impact of air quality on exacerbations during the COVID-19 lockdown,4 before highlighting what’s hot on social media. This week, the focus is on singing for lung health and how to better engage our patients!
1. Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available at: https://goldcopd.org/. Last accessed: November 2022;2. Sonnex K, et al. BMJ Open 2020;10:e037509;3. Au DH, et al. J Gen Intern Med 2009;24:457–463;4. Montiel-Lopez F, et al. ERJ Open Res 2022;8:00183–2022.
Disclosure:Dr Surya Bhatt Dr Bhatt has received grants from the National Institutes of Health, has served on advisory boards for Boehringer Ingelheim and Sanofi/Regeneron and has received continuing medical education fees from Integrity CE within the past 3 years.
Bio:
Dr Surya BhattDr Surya Bhatt is an Associate Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham (UAB), and is the Director of the UAB Lung Imaging Lab. He also serves as the Medical Director of the UAB Pulmonary Function Testing and Exercise Physiology Lab, and as the Medical Director of the UAB Telehealth and Center-based Pulmonary Rehabilitation programmes. His research focus is on developing new imaging metrics for the early diagnosis, phenotyping and precision-based therapy of COPD.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined this week by Professor James Chalmers, the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and Honorary consultant physician at Ninewells Hospital, to discuss the role of the lung microbiome in respiratory disease and the influence it may have on the management of COPD.1–3 Dr Russell will then share insights from an interesting new editorial which explores strategies implemented in the management of chronic respiratory disease in Finland from 1996–2018. 4 Finally, we delve into the social media hot topic of the week: advance care planning in COPD. Be sure to subscribe to the Medical Insider COPD podcast and never miss an episode!
1. Global Initiative for Chronic Obstructive Lung Disease 2022. Available at: here Last accessed: September 20222. Keir H, Contoli M, and Chalmers JD. Biomedicines 2021;9:1312; 3. Keir H, et al. Am J Respir Crit Care Med 2022;205:A5567;4. Tiina M, et al. Eur Respir J 2022;60:2200318
Disclosures Professor James Chalmers Professor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon. He has also received research grant support from AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Insmed and Novartis.
Bios:
Professor James Chalmers Professor James Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and an Honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult airways diseases, particularly bronchiectasis and COPD. He chaired the 2017 European Respiratory Society bronchiectasis guidelines and was also involved with 2020 Guidelines on inhaled corticosteroid use in COPD and the 2021 COVID-19 management guidelines. He is also deputy chief editor of the European Respiratory Journal and a member of the Editorial Board for the Medical Insider COPD Podcast series.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined this week by Professor David Newby, the Chair of Cardiology at the University of Edinburgh, Scotland, to discuss the overlap between COPD and cardiovascular disease in clinical practice. Listen as they explore the similarities between risk factors and patient presentation, which treatments are the most effective, and how cardiologists and respiratory physicians can work together to be the best for their patients. 1-4 Dr Russell will then highlight an interesting new paper on the associations between COPD and severe pulmonary hypertension,5 before delving into the social media hot topic of the week: mucus in the lungs.
1. Morgan AD, et al. Ther Adv Respir Dis 2018;12:1753465817750524; 2. Rabe KF, et al. Eur Respir Rev 2018;27:180057; 3. Visseren FLJ, et al. Eur Heart J 2021;42:3227–3337; 4. Rogliani P, et al. Int J Chron Obstruct Pulmon Dis 2017;12:3469–3485; 5. Dauriat G, et al. Eur Respir J 2022;60:2102897
Disclosures Professor David Newby Professor Newby reports fees from Amgen (consultancy, research projects), AstraZeneca (meetings, consultancy, lectures, research projects), Boehringer Ingelheim (meetings, lectures, research projects), Bristol Myers Squibb (meetings, consultancy, research projects), British Medical Journal (Deputy Editor of Heart), Cleerly (talks), Elsevier (books), Eli Lilly (meetings, consultancy), GE Healthcare (research projects), GlaxoSmithKline (meetings, consultancy, lectures, trial steering committee, research projects), Roche (research projects), IC Targets (research projects), Inositec (consultancy, research projects), Janssen/Johnson & Johnson (meetings, consultancy, research projects), Life Molecular Imaging (research projects), Medtronic (meetings), Nordic Pharma (research projects), Novartis (consultancy, research projects), Pfizer (meetings, consultancy, lectures, research projects), Sanofi (meetings, consultancy, lectures, research projects), Siemens (research projects), Silence Therapeutics (consultancy), Spacelabs Healthcare (research projects), Toshiba (meetings, consultancy, lectures, research projects), UCB Pharma (consultancy, data monitoring committee), Wyeth (research projects) and Zealand Pharma (consultancy).
Bios:
Professor David Newby Professor David Newby is the British Heart Foundation Duke of Edinburgh Chair of Cardiology at the University of Edinburgh, Director of the Edinburgh Clinical Research Facility, Director of the Edinburgh Imaging Facilities and a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh. He has major interests in experimental medicine, advanced imaging and clinical trials in cardiovascular disease. He has investigated the adverse cardiovascular effects of air pollution as well as the interplay between cardiovascular and respiratory disease.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.